{"id":1167054,"date":"2024-06-06T04:30:23","date_gmt":"2024-06-06T08:30:23","guid":{"rendered":"https:\/\/www.statnews.com\/?p=1167054"},"modified":"2024-06-06T11:25:38","modified_gmt":"2024-06-06T15:25:38","slug":"psychedelics-mdma-fda-growth-opportunity","status":"publish","type":"post","link":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/","title":{"rendered":"Psychedelics companies see FDA panel&#8217;s vote as a growth opportunity, not a roadblock"},"content":{"rendered":"<p>A day after a panel of advisers to the Food and Drug Administration expressed deep concerns about the use of MDMA to help treat post-traumatic stress disorder, companies working to develop other psychedelics said their optimism had not been dimmed \u2014\u00a0and that the concerns provided a clearer blueprint for what it might take to get such a drug approved.<\/p>\n<p>The advisory committee <a href=\"https:\/\/www.statnews.com\/2024\/06\/04\/fda-advisory-panel-mdma-therapy-ptsd\/\">overwhelmingly voted<\/a> that Lykos Therapeutics, which is seeking FDA approval for MDMA and therapist oversight, rather than just the drug itself, had failed to demonstrate that the therapy would be effective in treating PTSD. Members of the panel also concluded that the potential benefits of the treatment did not outweigh the risks, though they noted it was a promising treatment modality.<\/p>\n<p>STAT spoke with nearly a dozen companies developing psychedelics on Wednesday, and none seemed particularly shocked by the panel\u2019s findings, noting that Lykos\u2019 approach has been plagued with controversy for years.<\/p>","protected":false},"excerpt":{"rendered":"<p>STAT spoke with nearly a dozen companies developing psychedelics, and none seemed particularly shocked by an FDA panel&#8217;s rejection of MDMA-assisted therapy. <\/p>\n","protected":false},"author":133,"featured_media":933834,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"stat_display_restriction_not_latest":false,"stat_featured_image_caption":"","stat_featured_image_nocrop":false,"stat_featured_image_focal_point":{"x":0.5,"y":0.5},"stat_article_wordmark_img":[],"stat_article_wordmark_url":"","stat_article_wordmark_height":"125px","stat_article_wordmark_enable":false,"stat_article_subheadline":"","stat_paywall_restrict":true,"footnotes":"","stat_article_enhanced_byline":"","stat_article_newsletter_id":"","stat_article_header_color_scheme":"","_yoast_wpseo_primary_category":5318,"stat_paywall_move_flag":0},"categories":[5318],"tags":[294,1047,202512,5393],"authors":[3054],"class_list":["post-1167054","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma","tag-fda","tag-mental-health","tag-psychedelics","tag-stat-plus"],"featured_image_src":"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658-1024x649.jpeg","coauthors":[{"avatar":"<img width=\"80\" height=\"80\" src=\"https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-avatar-small2-80x80.png\" class=\"avatar\" alt=\"Meghana Keshavan\" loading=\"lazy\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" decoding=\"async\" srcset=\"https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-avatar-small2-80x80.png 80w, https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-avatar-small2-328x328.png 328w, https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-avatar-small2-500x500.png 500w, https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-avatar-small2-640x640.png 640w, https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-avatar-small2-576x576.png 576w, https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-avatar-small2-160x160.png 160w, https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-avatar-small2-645x645.png 645w, https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-avatar-small2.png 700w\" \/>","display_name":"Meghana Keshavan","author_page":"https:\/\/www.statnews.com\/staff\/meghana-keshavan\/","first_name":"Meghana","title":"Biotech Correspondent","bio":"Meghana Keshavan covers biotech and contributes to <a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">The Readout newsletter<\/a>.","email_address":"meghana.keshavan@statnews.com","email_url":"mailto:meghana.keshavan@statnews.com","twitter_url":"https:\/\/x.com\/megkesh","twitter_handle":"@megkesh","facebook_url":"","linkedin_url":"","web_url":"","bluesky_url":"","bluesky_handle":""}],"stat_card_curation":{"image_id":933834,"title":"","excerpt":"","video_id":0,"disable_topic_image_curation":false},"template_inline_styles":[],"stat_byline_classes":["article-byline","single-author"],"use_block_editor_for_post":false,"stat_featured_video":null,"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.5 (Yoast SEO v26.5) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Psychedelics companies see FDA panel vote as an opportunity for growth<\/title>\n<meta name=\"description\" content=\"\u201cMDMA is approvable, but we can have much more accessible and easier-to-work-with molecules and treatments,\u201d one CEO said.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Psychedelics companies see FDA panel&#039;s vote as a growth opportunity, not a roadblock\" \/>\n<meta property=\"og:description\" content=\"STAT spoke with nearly a dozen companies developing psychedelics, and none seemed particularly shocked by an FDA panel&#039;s rejection of MDMA-assisted therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/\" \/>\n<meta property=\"og:site_name\" content=\"STAT\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/statnews\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-06T08:30:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-06T15:25:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658-1024x576.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Meghana Keshavan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@megkesh\" \/>\n<meta name=\"twitter:site\" content=\"@statnews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Meghana Keshavan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/\"},\"author\":{\"name\":\"Meghana Keshavan\",\"@id\":\"https:\/\/www.statnews.com\/#\/schema\/person\/43d3754d214b1b11fc018c1f68d20528\"},\"headline\":\"Psychedelics companies see FDA panel&#8217;s vote as a growth opportunity, not a roadblock\",\"datePublished\":\"2024-06-06T08:30:23+00:00\",\"dateModified\":\"2024-06-06T15:25:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/\"},\"wordCount\":1342,\"publisher\":{\"@id\":\"https:\/\/www.statnews.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658.jpeg\",\"keywords\":[\"FDA\",\"Mental Health\",\"psychedelics\",\"STAT+\"],\"articleSection\":[\"Pharma\"],\"inLanguage\":\"en-US\",\"isAccessibleForFree\":\"False\",\"hasPart\":{\"@type\":\"WebPageElement\",\"isAccessibleForFree\":\"False\",\"cssSelector\":\".restricted-content-text\"},\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.statnews.com\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/\",\"url\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/\",\"name\":\"Psychedelics companies see FDA panel vote as an opportunity for growth\",\"isPartOf\":{\"@id\":\"https:\/\/www.statnews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658.jpeg\",\"datePublished\":\"2024-06-06T08:30:23+00:00\",\"dateModified\":\"2024-06-06T15:25:38+00:00\",\"description\":\"\u201cMDMA is approvable, but we can have much more accessible and easier-to-work-with molecules and treatments,\u201d one CEO said.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#primaryimage\",\"url\":\"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658.jpeg\",\"contentUrl\":\"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658.jpeg\",\"width\":6993,\"height\":4432,\"caption\":\"More than 60 compounds representing novel treatment approaches are in the pipeline, including psilocybin, the active ingredient in \u201cmagic mushrooms.\u201d\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.statnews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Psychedelics companies see FDA panel&#8217;s vote as a growth opportunity, not a roadblock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.statnews.com\/#website\",\"url\":\"https:\/\/www.statnews.com\/\",\"name\":\"STAT\",\"description\":\"A decade of reporting from the frontiers of health and medicine\",\"publisher\":{\"@id\":\"https:\/\/www.statnews.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.statnews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.statnews.com\/#organization\",\"name\":\"STAT\",\"url\":\"https:\/\/www.statnews.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.statnews.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.statnews.com\/wp-content\/uploads\/2016\/06\/Stat_Logo_150.png\",\"contentUrl\":\"https:\/\/www.statnews.com\/wp-content\/uploads\/2016\/06\/Stat_Logo_150.png\",\"width\":150,\"height\":41,\"caption\":\"STAT\"},\"image\":{\"@id\":\"https:\/\/www.statnews.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/statnews\/\",\"https:\/\/x.com\/statnews\",\"https:\/\/www.linkedin.com\/company\/stat-news\/\",\"https:\/\/www.youtube.com\/channel\/UC89FjSf9AT1O2qw6vxrrxDQ\"],\"description\":\"STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories from the places that matter to our readers \u2014 research labs, hospitals, executive suites, and political campaigns.\",\"legalName\":\"STAT\",\"foundingDate\":\"2015-11-01\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":\"51\",\"maxValue\":\"200\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.statnews.com\/#\/schema\/person\/43d3754d214b1b11fc018c1f68d20528\",\"name\":\"Meghana Keshavan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.statnews.com\/#\/schema\/person\/image\/3fb3a29fa1529c7e51b5371040749773\",\"url\":\"https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-profile-96x96.png\",\"contentUrl\":\"https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-profile-96x96.png\",\"caption\":\"Meghana Keshavan\"},\"description\":\"Meghana Keshavan is a biotech correspondent at STAT and co-writer of The Readout newsletter. She joined STAT in 2016. She has written about the life sciences industry for more than a decade. Before that, she worked for news outlets like Thomson Reuters, the Detroit Free Press, the Detroit Metro Times and NPR affiliate WDET. As a young lass, Meghana toiled five years as a research peon in a schizophrenia genetics lab. She once spilled ethidium bromide on herself, and might be a mutant.\",\"sameAs\":[\"https:\/\/x.com\/megkesh\"],\"url\":\"https:\/\/www.statnews.com\/staff\/meghana-keshavan\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Psychedelics companies see FDA panel vote as an opportunity for growth","description":"\u201cMDMA is approvable, but we can have much more accessible and easier-to-work-with molecules and treatments,\u201d one CEO said.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/","og_locale":"en_US","og_type":"article","og_title":"Psychedelics companies see FDA panel's vote as a growth opportunity, not a roadblock","og_description":"STAT spoke with nearly a dozen companies developing psychedelics, and none seemed particularly shocked by an FDA panel's rejection of MDMA-assisted therapy.","og_url":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/","og_site_name":"STAT","article_publisher":"https:\/\/www.facebook.com\/statnews\/","article_published_time":"2024-06-06T08:30:23+00:00","article_modified_time":"2024-06-06T15:25:38+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658-1024x576.jpeg","type":"image\/jpeg"}],"author":"Meghana Keshavan","twitter_card":"summary_large_image","twitter_creator":"@megkesh","twitter_site":"@statnews","twitter_misc":{"Written by":"Meghana Keshavan","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#article","isPartOf":{"@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/"},"author":{"name":"Meghana Keshavan","@id":"https:\/\/www.statnews.com\/#\/schema\/person\/43d3754d214b1b11fc018c1f68d20528"},"headline":"Psychedelics companies see FDA panel&#8217;s vote as a growth opportunity, not a roadblock","datePublished":"2024-06-06T08:30:23+00:00","dateModified":"2024-06-06T15:25:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/"},"wordCount":1342,"publisher":{"@id":"https:\/\/www.statnews.com\/#organization"},"image":{"@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658.jpeg","keywords":["FDA","Mental Health","psychedelics","STAT+"],"articleSection":["Pharma"],"inLanguage":"en-US","isAccessibleForFree":"False","hasPart":{"@type":"WebPageElement","isAccessibleForFree":"False","cssSelector":".restricted-content-text"},"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/www.statnews.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/","url":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/","name":"Psychedelics companies see FDA panel vote as an opportunity for growth","isPartOf":{"@id":"https:\/\/www.statnews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#primaryimage"},"image":{"@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658.jpeg","datePublished":"2024-06-06T08:30:23+00:00","dateModified":"2024-06-06T15:25:38+00:00","description":"\u201cMDMA is approvable, but we can have much more accessible and easier-to-work-with molecules and treatments,\u201d one CEO said.","breadcrumb":{"@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#primaryimage","url":"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658.jpeg","contentUrl":"https:\/\/www.statnews.com\/wp-content\/uploads\/2023\/03\/AdobeStock_390819658.jpeg","width":6993,"height":4432,"caption":"More than 60 compounds representing novel treatment approaches are in the pipeline, including psilocybin, the active ingredient in \u201cmagic mushrooms.\u201d"},{"@type":"BreadcrumbList","@id":"https:\/\/www.statnews.com\/2024\/06\/06\/psychedelics-mdma-fda-growth-opportunity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.statnews.com\/"},{"@type":"ListItem","position":2,"name":"Psychedelics companies see FDA panel&#8217;s vote as a growth opportunity, not a roadblock"}]},{"@type":"WebSite","@id":"https:\/\/www.statnews.com\/#website","url":"https:\/\/www.statnews.com\/","name":"STAT","description":"A decade of reporting from the frontiers of health and medicine","publisher":{"@id":"https:\/\/www.statnews.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.statnews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.statnews.com\/#organization","name":"STAT","url":"https:\/\/www.statnews.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.statnews.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.statnews.com\/wp-content\/uploads\/2016\/06\/Stat_Logo_150.png","contentUrl":"https:\/\/www.statnews.com\/wp-content\/uploads\/2016\/06\/Stat_Logo_150.png","width":150,"height":41,"caption":"STAT"},"image":{"@id":"https:\/\/www.statnews.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/statnews\/","https:\/\/x.com\/statnews","https:\/\/www.linkedin.com\/company\/stat-news\/","https:\/\/www.youtube.com\/channel\/UC89FjSf9AT1O2qw6vxrrxDQ"],"description":"STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories from the places that matter to our readers \u2014 research labs, hospitals, executive suites, and political campaigns.","legalName":"STAT","foundingDate":"2015-11-01","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"51","maxValue":"200"}},{"@type":"Person","@id":"https:\/\/www.statnews.com\/#\/schema\/person\/43d3754d214b1b11fc018c1f68d20528","name":"Meghana Keshavan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.statnews.com\/#\/schema\/person\/image\/3fb3a29fa1529c7e51b5371040749773","url":"https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-profile-96x96.png","contentUrl":"https:\/\/www.statnews.com\/wp-content\/uploads\/2021\/02\/meghana-k-profile-96x96.png","caption":"Meghana Keshavan"},"description":"Meghana Keshavan is a biotech correspondent at STAT and co-writer of The Readout newsletter. She joined STAT in 2016. She has written about the life sciences industry for more than a decade. Before that, she worked for news outlets like Thomson Reuters, the Detroit Free Press, the Detroit Metro Times and NPR affiliate WDET. As a young lass, Meghana toiled five years as a research peon in a schizophrenia genetics lab. She once spilled ethidium bromide on herself, and might be a mutant.","sameAs":["https:\/\/x.com\/megkesh"],"url":"https:\/\/www.statnews.com\/staff\/meghana-keshavan\/"}]}},"_links":{"self":[{"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/posts\/1167054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/users\/133"}],"replies":[{"embeddable":true,"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/comments?post=1167054"}],"version-history":[{"count":9,"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/posts\/1167054\/revisions"}],"predecessor-version":[{"id":1167268,"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/posts\/1167054\/revisions\/1167268"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/media\/933834"}],"wp:attachment":[{"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/media?parent=1167054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/categories?post=1167054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/tags?post=1167054"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.statnews.com\/wp-json\/wp\/v2\/authors?post=1167054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}